002262 恩华药业
已收盘 08-14 15:00:00
资讯
新帖
简况
恩华药业:NH600001乳状注射液临床试验受试者已全部出组
证券之星 · 08-04
恩华药业:NH600001乳状注射液临床试验受试者已全部出组
恩华药业:临床试验数据涉及知识产权和公司商业策略
证券之星 · 08-01
恩华药业:临床试验数据涉及知识产权和公司商业策略
研报掘金丨东吴证券:维持恩华药业“买入”评级,创新药梯队蓄势待发
格隆汇 · 08-01
研报掘金丨东吴证券:维持恩华药业“买入”评级,创新药梯队蓄势待发
恩华药业:公司自2023年起没有产品出口欧盟国家
证券之星 · 07-29
恩华药业:公司自2023年起没有产品出口欧盟国家
恩华药业(002262.SZ)发布上半年业绩,归母净利润7亿元,增长11.38%
智通财经 · 07-29
恩华药业(002262.SZ)发布上半年业绩,归母净利润7亿元,增长11.38%
恩华药业:公司会严格遵照信披规则进行信息披露工作
证券之星 · 07-18
恩华药业:公司会严格遵照信披规则进行信息披露工作
恩华药业获得发明专利授权:“一种沃替西汀前药的晶型、其制备方法和应用”
证券之星 · 07-11
恩华药业获得发明专利授权:“一种沃替西汀前药的晶型、其制备方法和应用”
恩华药业:安泰坦销售收入体现在商业医药和神经类子项目
证券之星 · 07-08
恩华药业:安泰坦销售收入体现在商业医药和神经类子项目
恩华药业:商业医药营收不包含安泰坦销售收入
证券之星 · 07-07
恩华药业:商业医药营收不包含安泰坦销售收入
恩华药业:公司主要产品为麻醉类和精神类产品
证券之星 · 06-27
恩华药业:公司主要产品为麻醉类和精神类产品
恩华药业:公司通过加快研发以及外部引进等方式调整产品结构
证券之星 · 06-25
恩华药业:公司通过加快研发以及外部引进等方式调整产品结构
恩华药业(002262.SZ)获董事长孙彭生增持23.79万股
智通财经 · 06-17
恩华药业(002262.SZ)获董事长孙彭生增持23.79万股
每周股票复盘:恩华药业(002262)召开2025年第一次临时股东大会,审议两项特别决议议案
证券之星 · 06-13
每周股票复盘:恩华药业(002262)召开2025年第一次临时股东大会,审议两项特别决议议案
恩华药业:公司产品福尔利(依托咪酯乳状注射液)为国内独家品种
证券之星 · 06-10
恩华药业:公司产品福尔利(依托咪酯乳状注射液)为国内独家品种
恩华药业与苑东生物达成战略合作
E公司 · 06-05
恩华药业与苑东生物达成战略合作
恩华药业获得发明专利授权:“芳烷基-4-(1H)吲哚基哌嗪衍生物、其制备方法和应用”
证券之星 · 06-03
恩华药业获得发明专利授权:“芳烷基-4-(1H)吲哚基哌嗪衍生物、其制备方法和应用”
江苏恩华药业股份有限公司药品申请临床试验默示许可获受理
金融界 · 06-03
江苏恩华药业股份有限公司药品申请临床试验默示许可获受理
恩华药业(002262.SZ)参股公司江苏好欣晴拟境外上市
智通财经 · 05-27
恩华药业(002262.SZ)参股公司江苏好欣晴拟境外上市
恩华药业:公司2024年报现金流量表中“支付其他与经营活动有关的现金”项目资金主要用在销售费用和研发费用
证券之星 · 05-09
恩华药业:公司2024年报现金流量表中“支付其他与经营活动有关的现金”项目资金主要用在销售费用和研发费用
恩华药业(002262)2025年一季报简析:营收净利润同比双双增长,应收账款上升
证券之星 · 04-19
恩华药业(002262)2025年一季报简析:营收净利润同比双双增长,应收账款上升
加载更多
公司概况
公司名称:
江苏恩华药业股份有限公司
所属行业:
医药制造业
上市日期:
2008-07-23
主营业务:
江苏恩华药业股份有限公司的主营业务是医药生产、研发和销售。公司的主要产品是力月西、福尔利、芬特、阿纷尼、恩利泽、欧立罗、泊得乐、必和、碳酸锂缓释片、维必朗、阿普唑仑片、恩卓欣、利鲁唑片。报告期内,公司荣获“2025中国药品研发综合实力前50强”荣誉,恩元医学检验实验室获得上海市创新型中小企业荣誉证书;恩元医学检验实验室获得信息安全管理、质量管理、环境管理、职业健康安全管理四体系认证。
发行价格:
5.68
{"stockData":{"symbol":"002262","market":"SZ","secType":"STK","nameCN":"恩华药业","latestPrice":23.53,"timestamp":1755154998000,"preClose":23.67,"halted":0,"volume":16364623,"delay":0,"changeRate":-0.0059,"floatShares":884000000,"shares":1016000000,"eps":1.1963,"marketStatus":"已收盘","change":-0.14,"latestTime":"08-14 15:00:00","open":23.67,"high":24.05,"low":23.43,"amount":387000000,"amplitude":0.0262,"askPrice":23.54,"askSize":399,"bidPrice":23.53,"bidSize":201,"shortable":0,"etf":0,"ttmEps":1.1963,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1755221400000},"marketStatusCode":5,"adr":0,"adjPreClose":23.67,"symbolType":"stock","openAndCloseTimeList":[[1755135000000,1755142200000],[1755147600000,1755154800000]],"highLimit":26.04,"lowLimit":21.3,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1015786583,"isCdr":false,"pbRate":3.13,"roa":"--","peRate":19.668979,"roe":"9.26%","epsLYR":1.13,"committee":0.251431,"marketValue":23901000000,"turnoverRate":0.0185,"status":1,"floatMarketCap":20798000000},"requestUrl":"/m/hq/s/002262","defaultTab":"news","newsList":[{"id":"2556802497","title":"恩华药业:NH600001乳状注射液临床试验受试者已全部出组","url":"https://stock-news.laohu8.com/highlight/detail?id=2556802497","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556802497?lang=zh_cn&edition=full","pubTime":"2025-08-04 17:33","pubTimestamp":1754299989,"startTime":"0","endTime":"0","summary":"证券之星消息,恩华药业(002262)08月04日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘你好,请问公司NH600001提交NDA的进展情况?恩华药业回复:答:NH600001原料药上市登记注册申请已于2025.07.29受理。NH600001乳状注射液临床试验研究受试者已全部出组,目前正在进行数据统计工作,待完成临床总结报告后将提交上市注册申请。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080400024138.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002262","BK0070","BK0239","BK0188"],"gpt_icon":0},{"id":"2556896472","title":"恩华药业:临床试验数据涉及知识产权和公司商业策略","url":"https://stock-news.laohu8.com/highlight/detail?id=2556896472","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556896472?lang=zh_cn&edition=full","pubTime":"2025-08-01 17:24","pubTimestamp":1754040268,"startTime":"0","endTime":"0","summary":"证券之星消息,恩华药业(002262)08月01日在投资者关系平台上答复投资者关心的问题。投资者提问:请问贵公司得一些关键临床试验得数据为什么不发布呢? 尤其是一些三期和二期结束得试验, 没有像其他公司一样发布试验结果数据是不是可以理解为, 试验得结果不太行?恩华药业回复:基于临床试验数据涉及知识产权和公司商业策略的考量,并遵守信息披露规则的要求,公司在定期报告及临时公告中及时披露了新药研发进展及取得的成果等重要信息。您对公司的关注和支持将推动我们更好地履行责任。谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080100029764.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","03347","BK1583","002262","BK0070","BK1576","BK1141","BK0239"],"gpt_icon":0},{"id":"2556886752","title":"研报掘金丨东吴证券:维持恩华药业“买入”评级,创新药梯队蓄势待发","url":"https://stock-news.laohu8.com/highlight/detail?id=2556886752","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556886752?lang=zh_cn&edition=full","pubTime":"2025-08-01 15:23","pubTimestamp":1754033003,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0028","159992","BK1574","BK0188","BK4134","BK0070","601555","002262","BK0183","09939","BK0276","BK0239","159938","06978","III","BK0012","BK1161","BK1515","BK0009"],"gpt_icon":0},{"id":"2555062727","title":"恩华药业:公司自2023年起没有产品出口欧盟国家","url":"https://stock-news.laohu8.com/highlight/detail?id=2555062727","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555062727?lang=zh_cn&edition=full","pubTime":"2025-07-30 07:30","pubTimestamp":1753831829,"startTime":"0","endTime":"0","summary":"证券之星消息,恩华药业(002262)07月30日在投资者关系平台上答复投资者关心的问题。投资者提问:请问贵公司自2023年起是否出口欧盟国家恩华药业回复:感谢您对公司的关注!公司自2023年起没有产品出口欧盟国家。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025073000005278.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","FSXEmain","002262","BK0239","FESXmain","BK0188"],"gpt_icon":0},{"id":"2555031397","title":"恩华药业(002262.SZ)发布上半年业绩,归母净利润7亿元,增长11.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2555031397","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555031397?lang=zh_cn&edition=full","pubTime":"2025-07-29 17:21","pubTimestamp":1753780913,"startTime":"0","endTime":"0","summary":"智通财经APP讯,恩华药业 发布2025年半年度报告,该公司营业收入为30.1亿元,同比增长8.93%。归属于上市公司股东的净利润为7亿元,同比增长11.38%。基本每股收益为0.69元。报告期,公司在研科研项目70余项,投入科研经费3.95亿元,比上年度同期增长了23.97%,取得了显著的研发成果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1323146.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"恩华药业(002262.SZ)发布上半年业绩,归母净利润7亿元,增长11.38%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002262"],"gpt_icon":0},{"id":"2552784456","title":"恩华药业:公司会严格遵照信披规则进行信息披露工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2552784456","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552784456?lang=zh_cn&edition=full","pubTime":"2025-07-18 11:42","pubTimestamp":1752810124,"startTime":"0","endTime":"0","summary":"证券之星消息,恩华药业(002262)07月18日在投资者关系平台上答复投资者关心的问题。投资者提问:我从证券之星得知恩华药业25年7月有两个专利获批,但公司未公告,公司网站也没有,其他上市公司有专利获批都会公告,请问这需要保密吗?恩华药业回复:答:公司非常重视技术创新和新药研发工作,并获得了大量的授权专利,这些授权专利,均可以通过公开渠道看到。公司会严格遵照信披规则进行信息披露工作,未有应披露而未披露的事项。感谢您对公司的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071800015317.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0070","BK0239","002262"],"gpt_icon":0},{"id":"2550017965","title":"恩华药业获得发明专利授权:“一种沃替西汀前药的晶型、其制备方法和应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2550017965","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550017965?lang=zh_cn&edition=full","pubTime":"2025-07-12 02:45","pubTimestamp":1752259558,"startTime":"0","endTime":"0","summary":"证券之星消息,根据天眼查APP数据显示恩华药业新获得一项发明专利授权,专利名为“一种沃替西汀前药的晶型、其制备方法和应用”,专利申请号为CN202210596543.9,授权日为2025年7月11日。本发明所得到的化合物的晶型I具有良好的晶型稳定性和化学稳定性,可更好地用于临床治疗,今年以来恩华药业新获得专利授权10个,较去年同期增加了233.33%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071200002969.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0188","002262","BK0239"],"gpt_icon":0},{"id":"2550579733","title":"恩华药业:安泰坦销售收入体现在商业医药和神经类子项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2550579733","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550579733?lang=zh_cn&edition=full","pubTime":"2025-07-09 07:39","pubTimestamp":1752017950,"startTime":"0","endTime":"0","summary":"证券之星消息,恩华药业07月09日在投资者关系平台上答复投资者关心的问题。谢谢恩华药业回复:尊敬的投资者您好!公司2024年报“营业收入构成”中“分行业”和“分产品”项目进行归类列示,其中“安泰坦”的销售收入分别对应体现在“商业医药”和“神经类”子项目之中。公司全资子公司“恩华和信”是侧重于销售本公司的自有产品,同时也着力销售代理梯瓦等合作公司的产品。感谢您对公司的关注!","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070900004640.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","BK1161","BK0188","BK0239","159938","002262","BK0070","BK1574","BK1515"],"gpt_icon":0},{"id":"2549589126","title":"恩华药业:商业医药营收不包含安泰坦销售收入","url":"https://stock-news.laohu8.com/highlight/detail?id=2549589126","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549589126?lang=zh_cn&edition=full","pubTime":"2025-07-07 16:30","pubTimestamp":1751877036,"startTime":"0","endTime":"0","summary":"证券之星消息,恩华药业(002262)07月07日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好!请问公司2024年报中显示的“ 商业医药 ”部分的营收779870356.72元,是否包含“安泰坦”的销售收入?恩华药业回复:尊敬的投资者您好!公司2024年报中显示的“ 商业医药 ”部分的营收779,870,356.72元,不包含“安泰坦”的销售收入。谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070700021279.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","09939","002262"],"gpt_icon":0},{"id":"2546713643","title":"恩华药业:公司主要产品为麻醉类和精神类产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2546713643","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546713643?lang=zh_cn&edition=full","pubTime":"2025-06-27 17:00","pubTimestamp":1751014854,"startTime":"0","endTime":"0","summary":"恩华连锁大药房主要销售的是国内制药企业生产的非管制类药品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062700027782.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","002262","BK0070"],"gpt_icon":0},{"id":"2546257441","title":"恩华药业:公司通过加快研发以及外部引进等方式调整产品结构","url":"https://stock-news.laohu8.com/highlight/detail?id=2546257441","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546257441?lang=zh_cn&edition=full","pubTime":"2025-06-25 09:15","pubTimestamp":1750814135,"startTime":"0","endTime":"0","summary":"证券之星消息,恩华药业(002262)06月25日在投资者关系平台上答复投资者关心的问题。投资者提问:请评估集采对公司未来利润影响如何?恩华药业回复:全国药品集中带量采购的常态化、制度化推进,对减轻患者负担,提高医保基金使用效率具有重要意义,公司对此项工作一直积极参与配合,坚决支持。国家药品集采对公司相关产品的销售业绩有一定的影响。公司通过加快研发以及外部引进等方式调整产品结构,主动适应市场环境的变化,努力保持公司业绩的稳定增长。谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062500008461.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002262","BK0070","BK0239"],"gpt_icon":0},{"id":"2544515369","title":"恩华药业(002262.SZ)获董事长孙彭生增持23.79万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2544515369","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544515369?lang=zh_cn&edition=full","pubTime":"2025-06-17 16:31","pubTimestamp":1750149078,"startTime":"0","endTime":"0","summary":"智通财经APP讯,恩华药业(002262.SZ)公告,公司董事长孙彭生先生于2025年6月16日以集中竞价交易方式增持公司A股股票23.79万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1306190.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002262","BK0188","BK0070","BK0239"],"gpt_icon":0},{"id":"2543307546","title":"每周股票复盘:恩华药业(002262)召开2025年第一次临时股东大会,审议两项特别决议议案","url":"https://stock-news.laohu8.com/highlight/detail?id=2543307546","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543307546?lang=zh_cn&edition=full","pubTime":"2025-06-14 04:48","pubTimestamp":1749847690,"startTime":"0","endTime":"0","summary":"截至2025年6月13日收盘,恩华药业报收于21.15元,较上周的22.66元下跌6.66%。本周,恩华药业6月10日盘中最高价报23.36元。本周关注点公司公告汇总:恩华药业召开2025年第一次临时股东大会,审议并通过两项特别决议议案股本股东变化:恩华药业将回购注销39.0209万股限制性股票,注册资本减少至101,578.6583万元公司公告汇总恩华药业于2025年6月13日召开了2025年第一次临时股东大会,会议地点为徐州市经济技术开发区龙湖西路31号恩华科技大厦3楼301会议室。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061400008363.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0070","002262","BK0239"],"gpt_icon":0},{"id":"2542395277","title":"恩华药业:公司产品福尔利(依托咪酯乳状注射液)为国内独家品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2542395277","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542395277?lang=zh_cn&edition=full","pubTime":"2025-06-10 16:12","pubTimestamp":1749543142,"startTime":"0","endTime":"0","summary":"证券之星消息,恩华药业(002262)06月10日在投资者关系平台上答复投资者关心的问题。投资者提问:想问一下,依托咪酯集采对公司的影响?恩华药业回复:公司产品福尔利(依托咪酯乳状注射液)为国内独家品种,在国家层面的集采可能性很小,但在部分地方组织的联采后续动态尚需评估。公司将加大创新药、高技术壁垒和高政策壁垒仿制药的研发力度,来应对联采带来的影响,公司会持续关注依托咪酯在省级联采的进展情况,将采取措施积极应对,力争保持更多的市场份额。谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061000022991.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002262","BK0188","BK0070","BK0239"],"gpt_icon":0},{"id":"2541704515","title":"恩华药业与苑东生物达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2541704515","media":"E公司","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2541704515?lang=zh_cn&edition=full","pubTime":"2025-06-05 14:18","pubTimestamp":1749104336,"startTime":"0","endTime":"0","summary":"人民财讯6月5日电,近日,成都苑东生物制药股份有限公司(简称“苑东生物”)奥沙西泮片(安绵泽®)正式获批上市。江苏恩华药业股份有限公司(简称“恩华药业”)就该产品与苑东生物达成独家商业化合作。恩华药业将加速推进奥沙西泮片的市场拓展和临床应用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250605141856a49af25e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250605141856a49af25e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0070","002262","BK0239","688513","BK0188"],"gpt_icon":0},{"id":"2540015297","title":"恩华药业获得发明专利授权:“芳烷基-4-(1H)吲哚基哌嗪衍生物、其制备方法和应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2540015297","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2540015297?lang=zh_cn&edition=full","pubTime":"2025-06-04 02:48","pubTimestamp":1748976496,"startTime":"0","endTime":"0","summary":"证券之星消息,根据天眼查APP数据显示恩华药业新获得一项发明专利授权,专利名为“芳烷基-4-吲哚基哌嗪衍生物、其制备方法和应用”,专利申请号为CN202210113063.2,授权日为2025年6月3日。特别地,本发明涉及通式所示的化合物、其制备方法及含有该化合物的药物组合物,及其在制备预防和/或治疗与哺乳动物5羟色胺受体和/或多巴胺受体相关的中枢神经系统疾病药物中的应用。今年以来恩华药业新获得专利授权8个,较去年同期增加了166.67%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060400001210.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","002262","BK0070"],"gpt_icon":0},{"id":"2540723937","title":"江苏恩华药业股份有限公司药品申请临床试验默示许可获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2540723937","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2540723937?lang=zh_cn&edition=full","pubTime":"2025-06-03 21:17","pubTimestamp":1748956677,"startTime":"0","endTime":"0","summary":"6月3日,据CDE官网消息,江苏恩华药业股份有限公司联合申请药品“NH104片”,获得临床试验默示许可,受理号CXHL2500311。江苏恩华药业股份有限公司,成立于1999年,位于徐州市,是一家以从事医药制造业为主的企业。通过天眼查大数据分析,江苏恩华药业股份有限公司共对外投资了19家企业,参与招投标项目4530次,知识产权方面有商标信息409条,专利信息275条,此外企业还拥有行政许可689个。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/06/03211750839601.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1576","BK1141","BK1583","BK0239","BK0188","BK0070","03347","002262"],"gpt_icon":0},{"id":"2538463917","title":"恩华药业(002262.SZ)参股公司江苏好欣晴拟境外上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2538463917","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2538463917?lang=zh_cn&edition=full","pubTime":"2025-05-27 19:27","pubTimestamp":1748345221,"startTime":"0","endTime":"0","summary":"智通财经APP讯,恩华药业 发布公告,江苏好欣晴移动医疗科技有限公司为公司参股公司,江苏好欣晴是一家专注于心理医疗和健康的专精特新企业,是首家为精神心理疾病领域提供科普预防、健康管理、疾病筛查、诊疗、康复管理以及智能系统和数字药物产品研发全周期解决方案的数字化高科技集团公司,是国家高新技术企业和专精特新企业。江苏好欣晴根据其发展需要,拟实施境外上市计划,拓展更多融资渠道推动其业务的发展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1298209.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002262","BK0070","BK0188","BK0239"],"gpt_icon":0},{"id":"2534940190","title":"恩华药业:公司2024年报现金流量表中“支付其他与经营活动有关的现金”项目资金主要用在销售费用和研发费用","url":"https://stock-news.laohu8.com/highlight/detail?id=2534940190","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534940190?lang=zh_cn&edition=full","pubTime":"2025-05-09 09:12","pubTimestamp":1746753131,"startTime":"0","endTime":"0","summary":"证券之星消息,恩华药业(002262)05月09日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘你好,贵公司2024财报现金流量表中,“ 支付其他与经营活动有关的现金”比去年增加了4亿多,主要是什么原因导致增加的?“ 支付其他与经营活动有关的现金”这部分资金主要用在什么地方?恩华药业回复:公司2024年报现金流量表中“ 支付其他与经营活动有关的现金”项目资金主要用在销售费用和研发费用。其同比增加是相关业务规模扩大所致。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050900006213.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0188","002262","BK0239"],"gpt_icon":0},{"id":"2528823048","title":"恩华药业(002262)2025年一季报简析:营收净利润同比双双增长,应收账款上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2528823048","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528823048?lang=zh_cn&edition=full","pubTime":"2025-04-20 06:10","pubTimestamp":1745100645,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期恩华药业发布2025年一季报。截至本报告期末,公司营业总收入15.11亿元,同比上升11.29%,归母净利润3.01亿元,同比上升13.35%。本报告期恩华药业应收账款上升,应收账款同比增幅达50.86%。去年的净利率为20.02%,算上全部成本后,公司产品或服务的附加值高。持有恩华药业最多的基金为汇添富创新医药混合,目前规模为46.75亿元,最新净值1.4016,较上一交易日下跌0.55%,近一年上涨6.38%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042000000636.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002262"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1755209948835,"stockEarnings":[{"period":"1week","weight":0.0195},{"period":"1month","weight":0.0899},{"period":"3month","weight":0.0868},{"period":"6month","weight":0.075},{"period":"1year","weight":-0.0899},{"period":"ytd","weight":-0.0177}],"compareEarnings":[{"period":"1week","weight":0.0074},{"period":"1month","weight":0.0461},{"period":"3month","weight":0.0888},{"period":"6month","weight":0.0955},{"period":"1year","weight":0.2862},{"period":"ytd","weight":0.0939}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏恩华药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"43626人(较上一季度增加30.17%)","perCapita":"20261股","listingDate":"2008-07-23","address":"江苏省徐州市鼓楼区经济技术开发区杨山路18号","registeredCapital":"101578万元","survey":" 江苏恩华药业股份有限公司的主营业务是医药生产、研发和销售。公司的主要产品是力月西、福尔利、芬特、阿纷尼、恩利泽、欧立罗、泊得乐、必和、碳酸锂缓释片、维必朗、阿普唑仑片、恩卓欣、利鲁唑片。报告期内,公司荣获“2025中国药品研发综合实力前50强”荣誉,恩元医学检验实验室获得上海市创新型中小企业荣誉证书;恩元医学检验实验室获得信息安全管理、质量管理、环境管理、职业健康安全管理四体系认证。","listedPrice":5.68},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.7","shortVersion":"4.34.7","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恩华药业(002262)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恩华药业(002262)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恩华药业,002262,恩华药业股票,恩华药业股票老虎,恩华药业股票老虎国际,恩华药业行情,恩华药业股票行情,恩华药业股价,恩华药业股市,恩华药业股票价格,恩华药业股票交易,恩华药业股票购买,恩华药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恩华药业(002262)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恩华药业(002262)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}